Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

Area of Science:

• Molecular Oncology
• Epigenetics
• Prostate Cancer Research

Background:

• Castration-resistant prostate cancer (CRPC) is a major concern for advanced prostate cancer patients.
• Androgen receptor (AR) signaling and epigenetic modifications are key drivers in CRPC development.

Purpose of the Study:

• To investigate the role of epigenetic modifications in CRPC development.
• To identify potential molecular markers for prostate cancer prognosis and tumor aggressiveness.

Main Methods:

• Comparative analysis of DNA methylation and gene expression profiles in androgen-sensitive and CRPC cells.
• Investigation of claudin-3 (CLDN3) epigenetic silencing mechanisms (DNA methylation, histone acetylation, H3K27 methylation).
• Functional studies on CLDN3 loss and its association with cellular invasion.
• Immunohistochemical analysis of CLDN3 expression in patient tumor samples and correlation with clinical outcomes.

Main Results:

• Epigenetic silencing of CLDN3 was observed in AR-positive, androgen-deprived prostate cancer cells (LNCaP-abl).
• CLDN3 silencing was associated with increased cellular invasion and decreased expression in CRPC patient samples.
• Reduced CLDN3 expression correlated with higher Gleason scores, locally advanced tumors, worse disease-free survival, and faster clinical progression.

Conclusions:

• Epigenetic silencing of CLDN3 is a frequent event in CRPC.
• CLDN3 can serve as a valuable prognostic molecular marker for prostate cancer patients.
• CLDN3 expression levels may help differentiate aggressive from indolent prostate tumors.